Thus far, PD-L1 has failed in this purpose and TMB evaluation, potentially linked to ICIs benefit when administered in pre-treated SCLC in retrospective evaluations [31,32], did not show predictive value in IMpower133 [24,26]. The gene discussed is CD274; the disease is small cell lung carcinoma.